{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:48:07Z","timestamp":1788691687578,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06503-x","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:19:54Z","timestamp":1751933994000},"page":"4855-4857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rapid withdrawal of voxelotor can precipitate sickle cell disease related crisis"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-5748","authenticated-orcid":false,"given":"Salam","family":"Alkindi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al Subhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Pathare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"6503_CR1","doi-asserted-by":"publisher","unstructured":"Piel FB, Hay S, Gupta S, Weatherall DJ, Williams TN [2013] global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions. PLoS Med 10(7):e1001484. https:\/\/doi.org\/10.1371\/journal.pmed.1001484","DOI":"10.1371\/journal.pmed.1001484"},{"key":"6503_CR2","doi-asserted-by":"publisher","unstructured":"Brousse V, Inusa B, Rees D (2023) Global burden of sickle cell disease in 2021. Lancet Haematol 10(10):e792. https:\/\/doi.org\/10.1016\/S2352-3026(23)00239-9","DOI":"10.1016\/S2352-3026(23)00239-9"},{"key":"6503_CR3","doi-asserted-by":"publisher","unstructured":"Lee MT, Ogu UO (2022) Sickle cell disease in the new era: advances in drug treatment. Transfus Apher Sci 61(5):103555. https:\/\/doi.org\/10.1016\/j.transci.2022.103555","DOI":"10.1016\/j.transci.2022.103555"},{"key":"6503_CR4","doi-asserted-by":"publisher","unstructured":"Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J HOPE trial investigators (2019) A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med 381(6):509\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1903212","DOI":"10.1056\/NEJMoa1903212"},{"key":"6503_CR5","doi-asserted-by":"publisher","unstructured":"Muschick K, Fuqua T, Stoker-Postier C, Anderson AR\u00a0(2022) Real-world data on voxelotor to treat patients with sickle cell disease. Eur J Haematol 109(2):154\u2013161. https:\/\/doi.org\/10.1111\/ejh.13782","DOI":"10.1111\/ejh.13782"},{"key":"6503_CR6","doi-asserted-by":"publisher","unstructured":"Alkindi S, Al Subhi A, Ali AEH, Pathare AV (2023) Influence of voxelotor-hemoglobin complexes in the estimation of hemoglobin S levels by the current standard of care laboratory evaluation techniques. Front Med (Lausanne). 10:1149281. eCollection https:\/\/doi.org\/10.3389\/fmed.2023.1149281","DOI":"10.3389\/fmed.2023.1149281"},{"key":"6503_CR7","doi-asserted-by":"crossref","unstructured":"Sarafa SL, Abdullahib SU, Akinsetec AM, Fasolad FA, Idowue M, Penningtonf S, Ershlerg WB, Staggh MP, Lisboni EA, Montealegre-Golcher\u00a0F (2024) Preliminary results from multi-center phase 2\/3 study of next generation hemoglobin polymerization inhibitor Osivelotor (GBT 021601) for the treatment of sickle cell disease. Hematol Transfusion Cell Ther 46(4):S30","DOI":"10.1016\/j.htct.2024.09.051"},{"key":"6503_CR8","doi-asserted-by":"publisher","unstructured":"Oksenberg D, Dufu K, Patel M, Chanuang C, Li Z, Xu Q, Silva-Garcis A, Zhou C, Hutchaleelaha A, Patskovska L, Patskpvsky Y, Almo SC, Sinha U, Metcalf BW Archer DR (2016) GBT440 increases hemoglobin oxygen affinity, reduces sickling, and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol 175(1):141\u2013153. https:\/\/doi.org\/10.1111\/bjh.14214","DOI":"10.1111\/bjh.14214"},{"key":"6503_CR9","doi-asserted-by":"publisher","unstructured":"Dufu K, Patel M, Oksenberg D, Cabrales P (2018) GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. Clin Hemorheol Microcirc 70(1):95\u2013105. https:\/\/doi.org\/10.3233\/CH-170340","DOI":"10.3233\/CH-170340"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06503-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06503-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06503-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:07Z","timestamp":1761283807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06503-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6503"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06503-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The original study was approved by the college of medicine & health sciences medical research & ethics committee (MREC #1677), and patient consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have agreed with the content of the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}